DSIP (Delta Sleep-Inducing Peptide)
Nine-amino acid neuropeptide first isolated in 1977
At a glance
What it is: Nine-amino acid neuropeptide first isolated in 1977.
Primary research applications:
- Claimed: sleep improvement
- Claimed: stress and chronic pain support
Editorial summary: DSIP was first described in the 1970s with claims of sleep-promoting activity, but decades of follow-up research have produced mixed and inconsistent results. It is not an established clinical sleep aid and should not be positioned as one.
What is DSIP?
DSIP is a nonapeptide originally isolated from rabbit cerebral venous blood after inducing delta-wave sleep by electrical stimulation. Its proposed role in sleep regulation has been investigated for nearly 50 years with inconsistent results.[1]
Mechanism of action
Proposed mechanisms include modulation of EEG delta activity, effects on stress-related HPA axis regulation, and general neuromodulatory effects. No single receptor target has been definitively characterized.
What the research shows
The peer-reviewed literature on DSIP is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity, supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Improves sleep quality in humans | Historical small studies; no modern confirmation | Preliminary |
| Reduces stress responses | Limited supporting data | Preliminary |
| Is a well-validated sleep aid | Not an established clinical tool | Unsupported |
Reported user experiences
How the research describes administration
Grey-market subcutaneous injection. No validated clinical protocol.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness; these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
⚠ Regulatory update (July 2026): On July 23-24, 2026 the FDA Pharmacy Compounding Advisory Committee (PCAC) declined to recommend DSIP for the 503A Bulks List, failing 6-7 with one abstention. It was the only one of the seven reviewed compounds the committee rejected, and the sole vote matching FDA staff's position. See our FDA PCAC July 2026 review for the full context.
DSIP is an old, under-substantiated peptide marketed for sleep. If it had a strong effect it would likely have been approved or become a standard sleep aid decades ago. Users who respond may be experiencing real but small effects; the average user is more likely to find benefit from addressing sleep hygiene or established interventions.
Frequently asked questions
Does DSIP actually help sleep?
The evidence is mixed. Some users report benefit; controlled studies have been inconsistent.
Is DSIP safe?
Reported tolerability is generally good. Long-term and high-dose safety isn't well-characterized.
Regulatory status (July 2026)
DSIP (emideltide) was one of seven peptides reviewed by the FDA Pharmacy Compounding Advisory Committee (PCAC) on July 23-24, 2026 for possible addition to the 503A Bulks List, evaluated for opioid withdrawal, chronic insomnia, and narcolepsy. On July 24 it was the only compound the committee declined to recommend, failing 6-7 with one abstention — the single vote of the two-day session that matched FDA staff's written position against the whole slate.
The committee recommended the other six. For DSIP (emideltide) the practical effect is that no path toward 503A compounding eligibility opened, and it remains not an FDA-approved drug. For the full picture across all seven compounds, see our July 2026 FDA PCAC review.
References
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA. 1977;74(3):1282-6. https://pubmed.ncbi.nlm.nih.gov/265569/
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-9. https://pubmed.ncbi.nlm.nih.gov/16539669/